Arun Chandnani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Arun Chandnani has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Samantha Hsieh
Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida
1 shared publication - Siyan Cao
Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA
1 shared publication
Latest Publications
- Open Access
- 20 December 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (12) , 2910
Bile Acids in Inflammatory Bowel Disease: From Pathophysiology to Treatment
Inflammatory bowel disease (IBD) is a chronic condition that affects about 7 million people worldwide, and new therapies are needed. Understanding the complex roles that bile acids (BAs) play in IBD may lead to the development of novel IBD treatments independent of direct immunosuppression. This review discusses the latest discoveries in the roles BAs play in IBD pathogenesis and explores how these discoveries offer promising new therapeutic targets to treat IBD and improve patient outcomes. Several therapies discussed include specific BA receptor (BAR) agonists, dietary therapies, supplements, probiotics, and mesenchymal stem cell therapies that have all been shown to decrease IBD disease activity.
- 20 December 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (12) , 2910
Open AccessBile Acids in Inflammatory Bowel Disease: From Pathophysiology to Treatment
Inflammatory bowel disease (IBD) is a chronic condition that affects about 7 million people worldwide, and new therapies are needed. Understanding the complex roles that bile acids (BAs) play in IBD may lead to the development of novel IBD treatments independent of direct immunosuppression. This review discusses the latest discoveries in the roles BAs play in IBD pathogenesis and explores how these discoveries offer promising new therapeutic targets to treat IBD and improve patient outcomes. Several therapies discussed include specific BA receptor (BAR) agonists, dietary therapies, supplements, probiotics, and mesenchymal stem cell therapies that have all been shown to decrease IBD disease activity.